Trial Details 60 Total Sites

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

New York City, New York
facility
Memorial Sloan Kettering Cancer Center ( Site 0026)
facility
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057)
2 facilities
Recruiting
Los Angeles, California
facility
Cedars Sinai Medical Center ( Site 0002)
1 facility
Recruiting
San Francisco, California
facility
UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007)
1 facility
Recruiting
Seattle, Washington
facility
Virginia Mason Medical Center ( Site 0052)
facility
Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093)
2 facilities
Recruiting
Baltimore, Maryland
facility
University of Maryland ( Site 0050)
1 facility
Recruiting
Tucson, Arizona
facility
The University of Arizona Cancer Center - North Campus ( Site 0011)
1 facility
Recruiting
Aurora, Colorado
facility
Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092)
1 facility
Recruiting
Lincoln, Nebraska
facility
Cancer Partners of Nebraska ( Site 0051)
1 facility
Recruiting
Lexington, Kentucky
facility
Markey Cancer Center ( Site 0018)
1 facility
Recruiting
Sioux Falls, South Dakota
facility
Sanford Hematology Oncology-Sioux Falls SD ( Site 0012)
1 facility
Recruiting
Fullerton, California
facility
St Joseph Heritage Healthcare-Oncology ( Site 0056)
1 facility
Recruiting
St. George, Utah
facility
Intermountain Healthcare ( Site 0043)
1 facility
Recruiting